Navigation Links
Time Magazine Names Agendia Test a Best Invention of 2007
Date:12/4/2007

Important Recognition for Dutch Prognostic Breast Cancer Test MammaPrint(R)

AMSTERDAM, the Netherlands, December 4 /PRNewswire/ -- TIME Magazine has named a new Dutch breast cancer test as one of the best inventions of 2007. This so called "Cancer's Crystal Ball" (MammaPrint(R)) invented and developed by the International company Agendia, gives additional information on the patient's own tumor to support the choice of treatment for that specific patient providing hope to all women who have been diagnosed with breast cancer.

"We are very pleased that we can help millions of women and that TIME has recognized our contribution to the advancement of health care across the globe, most notably in the field of oncology," said Bernhard Sixt, CEO and founder of Agendia. "This honour is a testament to our ongoing commitment to developing state-of-the-art technology for the benefit of cancer patients - not just in the field of breast cancer. In time, I think we'll be able to reach more people than ever before."

The Breast Cancer Test (MammaPrint(R)) measures the activity levels of 70 genes in a sample taken from a woman's surgically-removed breast cancer tumour. It then uses a specific algorithm to determine whether there is a low-risk or high-risk of the cancer spreading to another part of the body. The result can be used to assist physicians in identifying the most suitable treatment and often means that less aggressive therapies can be applied. The Breast Cancer Test is the first test of its kind to have received market clearance by the FDA.

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumour gene expression profiling. Agendia was the first company to commercialize such prognostic test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)*, is a diagnostic test to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary". Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation.

Agendia maintains close ties with several leading academic centres to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.

http://www.agendia.com

* CupPrint (R) is based on a license to the TUO database of AviaraDx


'/>"/>
SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Heartline(R) Fitness Systems Named to Inc. Magazines Inaugural List of the 5000 Fastest Growing Private Companies in U.S....
2. National Osteoporosis Foundation Teams Up With Ladies Home Journal Magazine to Launch a 10-city Mall Walk Tour
3. Martopia(R) Forms Strategic Alliance With Modern Healthcare Magazine
4. Inc. Magazine Reveals Its 26th Annual List of Americas 500 Fastest-Growing Private Companies
5. Meeting Expectations Named to First Annual CMI 25 List by Corporate Meetings & Incentives Magazine
6. Allure Magazine Names Remergent(R) DNA Repair Formula Best of Beauty
7. Northern Michigan Regional Health System Named a Working Mother 100 Best Company - 2007 by Working Mother Magazine
8. MEDRAD Plant Named IndustryWeek Magazine Award Finalist
9. Almost Family Named One of Ten Best Newcomers to Forbes Magazine 200 Best Small Companies
10. Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine
11. National Magazine Ranks Highmark 62nd Among Nations 500 Most Innovative Users of Information Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... The ... is slated to host the 2016 National SACA Leadership Conference on the Portland ... officers and chapter officers to come together and develop skills to be future ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... among Pittsburgh-area schoolchildren has found that more than 40 percent of participating fifth-grade ... MD , Director of Allergy and Asthma Clinical Research in the Division of ...
(Date:5/5/2016)... ... 2016 , ... In order to increase comfort, convenience and ... Seattle-based steam bath and sauna manufacturer recently launched amerecConnect™ , a new ... app, developed for both smartphones and personal computers perfectly emulates that of the ...
(Date:5/5/2016)... Ohio (PRWEB) , ... May 05, 2016 , ... United ... Cycle. , Clark brings more than 15 years of experience within the healthcare ... from a successful career as the Director of Patient Financial Services at Spectrum Health. ...
(Date:5/5/2016)... ... 2016 , ... CURE Media Group , the nation’s leading digital and ... Imerman Angels to expand outreach and emotional support for patients of all ... an emotional lifeline to patients and families facing the challenges of cancer diagnosis and ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 According to ... entitled "Brain Computer Interface Market - Global Industry Analysis, Size, ... brain computer interface (BCI) market  is expected to reach ... is estimated to expand at a CAGR of 14.9 ... A BCI device provides collaboration between the ...
(Date:5/4/2016)... 4, 2016 According to market research ... Demand Forecast to 2022 - Industry Insights by Slice Type ... and Others)" by P&S Market Research, the global computed ... and it is expected to grow at a CAGR of ... type segment is expected to witness the faster growth, CAGR ...
(Date:5/4/2016)... , May 4, 2016 ... completion of an alternative public offering (APO). This was ... operating company, Valeritas, Inc. and a private placement of ... at $5.00 per share. Under the terms ... 3, 2016, Valeritas Holdings, Inc. will trade on the ...
Breaking Medicine Technology: